Search Results

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease

Voltron Therapeutics, Inc announced that it has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.

DIMERx, Inc., an advance-stage biopharmaceutical company, announced that it has secured rights from Massachusetts General Hospital for a novel amino acid dimer to be developed for two rare disease indications in the U.S. and as a proprietary medical food for ex-U.S. markets.